The STAT3 Inhibitor GPB730 Enhances the Sensitivity to Enzalutamide in Prostate Cancer Cells

Enzalutamide and GPB730 treated LNCaP and C4–2 cells were subjected to western blot and QPCR analyses in order to investigate the expression of androgen receptor (AR), Signal Transducer and Activator of Transcription 3 (STAT3) and down-stream targets.